.webp)
2 days ago
3
Annalisa Morgan, MD, reflects on insights gained from the Consortium of Multiple Sclerosis Centers 2024 Annual Meeting regarding the management of multiple sclerosis (MS). She emphasizes the significance of data influencing clinical practice, particularly in patients with new-onset highly inflammatory relapsing-remitting MS, and although expecting to continue to favor an early high-efficacy therapy approach, acknowledges the potential for lower-efficacy therapies and an escalation approach in certain cases.
Extended-interval dosing of anti-CD20 therapies, especially in patients experiencing side effects or those with well-controlled MS, is also considered. In regard to discontinuation of medications, Dr Morgan suggests that it may apply primarily to older patients with stable disease. Finally, the importance of lifestyle modifications and symptom management was not overlooked at the conference. Overall, Dr Morgan anticipates incorporating new findings into clinical practice and looks forward to future research to enhance MS care.
English (US)